2. Kura Oncology receives fast track designation for tipifarnib in HRAS mutant HNSCC and provides enrollment guidance for AIM-HN trial. News release. San Diego, California. December 16, 2019. Accessed July 17, 2020. bit.ly/3fzFWA6.